Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RBT-9 for Prevention of COVID-19 Progression in High-Risk Individuals
NCT04364763Phase 2Terminated
- Sponsor
- Renibus Therapeutics
- Start
- Aug 2020
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in coronavirus disease 2019 (COVID-19) comparing RBT-9 with Placebo (2 arms). Primary endpoint: Clinical Status on WHO Ordinal Scale at 28 days. Started Aug 2020; status: terminated.
02
Drugs
tin protoporphyrin IX
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04364763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04364763.